Drug Trial Radar · NCT05046106
MLC1501 Study Assessing Efficacy in STROke Recovery
Last checked: Nov 19, 2026Latest source record: Mar 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Jan 2025
Primary completion
Sep 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Moleac Pte Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.
Conditions
- Stroke
- Stroke, Ischemic
- Strokes Thrombotic
- Stroke Sequelae
- Stroke, Cardiovascular
- Stroke, Embolic
- Stroke, Cryptogenic
Interventions
MLC1501Drug
Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
PlaceboOther
Caramel, chocolate brown, flavor (E\_1982648), dextrin
Primary outcomes
What the sponsor says the trial is designed to measure.
- modified Rankin ScaleTime frame: 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.